Introduction
============

Major depressive disorder (MDD) is a common, debilitating psychiatric disorder.[@b1-ndt-15-657] Venlafaxine, as a serotonin and norepinephrine reuptake inhibitor, is one of the major prescribed medications for MDD.[@b2-ndt-15-657] Previous studies implicate glutamate system genes, the glycogen synthase kinase-3β (*GSK-3β*) and brain-derived neurotrophic factor (*BDNF*), are involved in both pathophysiology of MDD and antidepressant treatment.[@b3-ndt-15-657] Furthermore, *BDNF* gene promotes the growth of neurons in vitro mediated by *GSK-3β*.[@b4-ndt-15-657] However, pharmacogenetic studies of *GSK-3β* and *BDNF* genes with antidepressant response are controversial in the literature.[@b5-ndt-15-657]--[@b8-ndt-15-657] Therefore, we attempted to investigate whether *GSK-3β* and *BDNF* gene polymorphisms are associated with venlafaxine treatment in the Han population.

For pharmacogenetics association study, 193 MDD patients in Chinese Han population (aged 18--65 years, no blood relationship) were recruited. All subjects recruited were of Han Chinese origin. Participants were first-onset patients. They did not receive any antidepressant treatment for at least 2 weeks and had no electroconvulsive therapy. Efficacy of treatment was determined by 17-item Hamilton Rating Scale, and all MDD patients had a minimum baseline Hamilton Rating Scale for Depression (HAMD) score of 18 points. Clinical interviews were performed by board-certified and experienced psychiatrists. The study was approved by the Ethics Committee of the Human Genetics Center in Shanghai and conducted in accordance with the Declaration of Helsinki. All subjects signed the informed consent form.

All MDD patients received a continuous antidepressant treatment for \>6 weeks. A total venlafaxine dose of 75--375 mg/day was used based on patients' conditions. Patients were evaluated at the end of weeks 1, 2, 4, and 6. Patients who have \>50% reduction of HAMD score were assigned to response group, and \<50% were assigned to nonresponse group at the end of week 6.[@b9-ndt-15-657] Other psychotropic medications were not allowed during the study except an eligible dose of benzodiazepine for insomnia at bedtime.

Genomic DNA extraction was carried out according to standard procedures with phenol/chloroform purification. Five single nucleotide polymorphisms (SNPs) (intron: rs4624596, rs182839, rs334533, and rs16830730; promoter: rs11925868) in *GSK-3β* and four SNPs (downstream: rs925946; 3′ UTR: rs7124442; exon: rs6265; promoter: rs908867) in *BDNF* gene based on the lit erature10,11 and the NCBI dbSNP database (<http://www.ncbi.nlm.nih.gov/SNP>). Genotyping of all SNPs was performed by a matrix-assisted laser desorption/ionization time-of-flight mass spectrometer using the MassARRAY^®^ Analyzer 4 platform (Sequenom, San Diego, CA, USA).

Demographic differences between responders and non-responders were calculated by the Student's *t*-test (age, age of onset, body mass index, and HAMD score) or Pearson's chi-squared test (gender, marital status, education, and family history). The SPSS Statistics Version 22 and R software (Lucent Technologies, Morris Plains, NJ, USA) were used to carry out the above analyses. Interrater reliability was evaluated by Kappa coefficients (Kappa value =0.85).[@b12-ndt-15-657] The online software SHEsis (<http://202.120.31.177/myanalysis.php>)[@b13-ndt-15-657] and R (version 3.2.2) were used to analyze allelic and genotypic distributions. HaploView version 4.2 was used to estimate linkage disequilibrium of all pairs of SNPs with *D*′, which is the standard measurement.[@b14-ndt-15-657] Hardy--Weinberg equilibrium (HWE) was calculated by using SHEsis. For all analyses, *P*-values were shown as two-tailed, and *P*\<0.05 was considered statistically significant.

In our study, 175 MDD patients completed the 6-week venlafaxine treatment, in which 146 (83%) patients were responders and the remaining 29 (27%) participants who gave no response at the end of week 6 were termed as nonresponders. The endpoint values for responders and nonresponders of HAMD were 16.24±5.49 and 6.04±3.57, respectively. We found no significant difference between responders and nonresponders in age, BMI, number of episodes, HAMD baseline score, family history, marital status, education years, and gender except for 6-week HAMD score (*P*\<0.05). Thus, it is reasonable to conclude that no systematic differences can potentially affect clinical outcomes between the responders and nonresponders.

None of the SNPs showed significantly deviated HWE (*P*\<0.05). Genotypes of response group vs nonresponse group were distributed as follows: rs4624596 C/T 84:12, T/T 35:7, C/C 27:10; rs182839 A/A 129:25, G/G 1:0, A/G 16:4; rs334533 A/A 39:13, G/G 26:4, A/G 81:12; rs11925868 C/C 122:25, C/A 23:4, A/A 1:0; rs16830730 G/G 53:9, A/A 33:7, A/G 60:13; rs925946 G/G 135:27, T/G 11:2; rs7124442 T/T 131:25, C/T 14:4, C/C 1:0; rs6265 G/G 34:6, A/A 41:5 A/G 71:18; rs908867 G/G 140:27, A/G 6:2. There is no significant difference observed between response and nonresponse groups in allele or genotype distributions (*P*\>0.05), which is shown in [Table S1](#SD1-ndt-15-657){ref-type="supplementary-material"}. We also calculated *D*′ and *r*^2^ for all combinations of the four SNPs (data not shown). The haplotype distributions showed no significant association between all combinations of these SNPs with antidepressant efficacy in MDD patients.

The association between polymorphism rs6265 of *BDNF* gene and antidepressant treatment outcome has always been inconsistent.[@b15-ndt-15-657] The polymorphism has been proven to be not associated with venlafaxine treatment response in our generalized anxiety disorder population.[@b16-ndt-15-657] Our result indicated that the polymorphism was negative in MDD samples. Additionally, the other three common SNPs in *BDNF* gene and *GSK-3β* gene were not associated with venlafaxine treatment in our Chinese MDD patients. However, there are some limitations in our study. Replicated studies with larger sample sizes and more common or rare variants are necessary to verify this association. A placebo control would offer a convincing estimation of the response rate and validate the association between the gene and venlafaxine treatment. Whereas, we did not use it due to high suicide rate in MDD patients. Furthermore, the phenotype of venlafaxine responses can be revealed with detailed genotypes.[@b17-ndt-15-657] Despite these, the current study may shed new light on predicting venlafaxine responses in MDD treatment.

Supplementary material
======================

###### 

Genotype and allele distributions of *GSK3β* and *BDNF* polymorphisms in response and nonresponse groups to venlafaxine

  Gene         SNP ID        Allele frequency   OR (95% CI)   *χ*^2^                 *P*-value[a](#tfn1-ndt-15-657){ref-type="table-fn"}   Genotype frequency                 *χ*^2^       *P*-value[a](#tfn1-ndt-15-657){ref-type="table-fn"}   HWE                     
  ------------ ------------- ------------------ ------------- ---------------------- ----------------------------------------------------- -------------------- ------------- ------------ ----------------------------------------------------- ------- ------- ------- --
                                                                                                                                                                                                                                                                         
  *GSK3β*      rs4624596                        C             T                                                                                                               C/T          T/T                                                   C/C                     
               Response      138 (0.472)        154 (0.527)   1.373 (0.779--2.419)   1.212                                                 0.270                84 (0.575)    35 (0.239)   27 (0.184)                                            4.076   0.130   0.176   
               Nonresponse   32 (0.551)         26 (0.448)                                                                                                      12 (0.413)    7 (0.241)    10 (0.344)                                                            0.678   
  rs182839                   A                  G                                                                                                               A/A           G/G          A/G                                                                           
               Response      274 (0.938)        18 (0.061)    0.886 (0.288--2.723)   0.044                                                 0.833                129 (0.883)   1 (0.006)    16 (0.109)                                            0.381   0.826   0.816   
               Nonresponse   54 (0.931)         4 (0.068)                                                                                                       25 (0.862)    0 (0)        4 (0.137)                                                             0.923   
  rs334533                   A                  G                                                                                                               A/A           G/G          A/G                                                                           
               Response      159 (0.544)        133 (0.455)   1.589 (0.882--2.862)   2.407                                                 0.120                39 (0.267)    26 (0.178)   81 (0.554)                                            3.804   0.149   0.359   
               Nonresponse   38 (0.655)         20 (0.344)                                                                                                      13 (0.448)    4 (0.137)    12 (0.413)                                                            0.902   
  rs11925868                 C                  A                                                                                                               C/C           C/A          A/A                                                                           
               Response      267 (0.914)        25 (0.085)    1.264 (0.422--3.779)   0.176                                                 0.674                122 (0.835)   23 (0.157)   1 (0.006)                                             0.279   0.869   0.997   
               Nonresponse   54 (0.931)         4 (0.068)                                                                                                       25 (0.862)    4 (0.137)    0 (0)                                                                 0.923   
  rs16830730                 G                  A                                                                                                               G/G           A/A          A/G                                                                           
               Response      166 (0.568)        126 (0.431)   0.871 (0.495--1.534)   0.227                                                 0.633                53 (0.363)    33 (0.226)   60 (0.41)                                             0.295   0.862   0.145   
               Nonresponse   31 (0.534)         27 (0.465)                                                                                                      9 (0.31)      7 (0.241)    13 (0.448)                                                            0.867   
  *BDNF*       rs925946                         G             T                                                                                                               G/G                                                                T/G                     
               Response      281 (0.962)        11 (0.037)    1.096 (0.236--5.08)    0.013                                                 0.906                135 (0.924)                11 (0.075)                                            0.014   0.904   0.897   
               Nonresponse   56 (0.965)         2 (0.034)                                                                                                       27 (0.931)                 2 (0.068)                                                             0.96    
  rs7124442                  T                  C                                                                                                               T/T           C/T          C/C                                                                           
               Response      276 (0.945)        16 (0.054)    0.782 (0.251--2.431)   0.180                                                 0.671                131 (0.897)   14 (0.095)   1 (0.006)                                             0.647   0.723   0.668   
               Nonresponse   54 (0.931)         4 (0.068)                                                                                                       25 (0.862)    4 (0.137)    0 (0)                                                                 0.923   
  rs6265                     G                  A                                                                                                               G/G           A/A          A/G                                                                           
               Response      139 (0.476)        153 (0.523)   1.179 (0.671--2.072)   0.329                                                 0.566                34 (0.232)    41 (0.28)    71 (0.486)                                            2.012   0.365   0.954   
               Nonresponse   30 (0.517)         28 (0.482)                                                                                                      6 (0.206)     5 (0.172)    18 (0.62)                                                             0.425   
  rs908867                   G                  A                                                                                                               G/G                        A/G                                                                           
               Response      286 (0.979)        6 (0.02)      0.587 (0.115--2.985)   0.420                                                 0.516                140 (0.958)                6 (0.041)                                             0.430   0.511   0.959   
               Nonresponse   56 (0.965)         2 (0.034)                                                                                                       27 (0.931)                 2 (0.068)                                                             0.960   

**Note:**

Pearson's *P*-value.

**Abbreviations:** HWE, Handy--Weinberg equilibrium; SNP, single nucleotide polymorphism.
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